Allergan plc Ordinary Shares (AGN) is Initiated by Credit Suisse to Outperform, Price Target at $327

Allergan plc Ordinary Shares (AGN) was Initiated by Credit Suisse to “Outperform” and the brokerage firm has set the Price Target at $327. Credit Suisse advised their investors in a research report released on Jul 25, 2016.

Many Wall Street Analysts have commented on Allergan plc Ordinary Shares. Credit Suisse Initiated Allergan plc Ordinary Shares on Jul 25, 2016 to “Outperform”, Price Target of the shares are set at $327.Shares were Reiterated by Mizuho on May 13, 2016 to “Neutral” and Lowered the Price Target to $ 232 from a previous price target of $250 .

On the company’s financial health, Allergan plc Ordinary Shares reported $3.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 10, 2016. Analyst had a consensus of $3.01. The company had revenue of $3796.00 million for the quarter, compared to analysts expectations of $3949.70 million. The company’s revenue was up 48.1% compared to the same quarter last year.

Allergan plc Ordinary Shares opened for trading at $244 and hit $247.44 on the upside on Wednesday, eventually ending the session at $246.95, with a gain of 1.78% or 4.31 points. The heightened volatility saw the trading volume jump to 22,12,832 shares. Company has a market cap of $97,683 M.

In a different news, on Jun 6, 2016, Maria Teresa Hilado (CFO) purchased 661 shares at $241.57 per share price. According to the SEC, on May 12, 2016, Nesli Basgoz (director) sold 459 shares at $225.10 per share price. On Aug 24, 2015, Brent L Saunders (CEO) purchased 1,000 shares at $301.94 per share price, according to the Form-4 filing with the securities and exchange commission.

Allergan plc Ordinary Shares

Leave a Reply

Allergan plc Ordinary Shares - Is it time to Sell?

Top Brokerage Firms are advising their investors on Allergan plc Ordinary Shares. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.